Last reviewed · How we verify
NCT04181567
Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
Phase 4 trial testing electroconvulsive therapy in Major Depressive Disorder in 97 participants. Completed in 22 November 2019.
8 October 2019
Quick facts
| Lead sponsor | Kaohsiung Kai-Suan Psychiatric Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 97 |
| Start date | 3 March 2014 |
| Primary completion | 8 October 2019 |
| Estimated completion | 22 November 2019 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- electroconvulsive therapy
- agomelatine (AGOMELATINE) — full drug profile →
- Placebo
Conditions studied
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
Sponsor
Kaohsiung Kai-Suan Psychiatric Hospital
Who can join
18 and older, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants. The purpose of this study is to compare the efficacy, safety, and time to relapse/recurrence of ECT to ECT plus agomelatine in the treatment of patients with major depressive disorder. Inpatients with major depressive disorder for ECT will be randomly assigned to double-blind treatment with placebo or agomelatine 50 mg/d.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04181567
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of electroconvulsive therapy
Trials testing the same drug.
- NCT05515159 — Blood Biomarkers in Electroconvulsive Therapy · enrolling by invitation
- NCT02871141 — Multimodal Imaging of ECT Effects · completed
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting
Other Kaohsiung Kai-Suan Psychiatric Hospital trials
Trials by the same sponsor.
- NCT04389476 — The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes · unknown
- NCT04426565 — The Follow-up Study for the Patients of Illicit Substance Use Disorder · NA · unknown
- NCT04093960 — Escitalopram Plus PS128 vs. Escitalopram · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04181567 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kaohsiung Kai-Suan Psychiatric Hospital
- Last refreshed: 29 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04181567.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing